Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 10,000 shares at $49.79 ($499K) on 2025-02-18, disclosed to the SEC on 2025-02-21.
Scheduled sale ($499k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.79 | 9,100 | $453K | 90.9% |
| 2 | $50.63 | 900 | $46K | 9.1% |
| Total | $49.87 avg | 10,000 | $499K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |